

Schnizer, Richard

To: STIC-ILL
Subject: 09/360,199

Please send me a copy of:

TI Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.

AU Gallichan W S; Johnson D C; Graham F L; Rosenthal K L

SO JOURNAL OF INFECTIOUS DISEASES, (1993 Sep) 168 (3) 622-9.

TI DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

AU Bourne N;

SO VACCINE, (1996 Sep) 14 (13) 1230-4.

TI Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract.

AU Rosenthal K L; Gallichan W S

SO SEMINARS IN IMMUNOLOGY, (1997 Oct) 9 (5) 303-14. Ref: 96

TI Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus.

AU Gallichan W S; Rosenthal K L

SO VACCINE, (1995 Nov) 13 (16) 1589-95.

TI Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization.

AU Gallichan W S; Rosenthal K L

CS Department of Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada.

SO JOURNAL OF INFECTIOUS DISEASES, (1998 May) 177 (5) 1155-61.

Bernstein et al (Vaccine 17: 1681-1689, 1999)

TI Recent progress in herpes simplex virus immunobiology and vaccine research.

AU Koelle David M; Corey Lawrence

SO CLINICAL MICROBIOLOGY REVIEWS, (2003 Jan) 16 (1) 96-113. Ref: 302

TI Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.

AU Mertz G J; Ashley R; Burke R L; Benedetti J; Critchlow C; Jones C C; Corey

SO JOURNAL OF INFECTIOUS DISEASES, (1990 Apr) 161 (4) 653-60.

TI Herpes. Vaccines for HSV.

AU Stanberry L R

CS University of Cincinnati College of Medicine, Ohio, USA.

SO DERMATOLOGIC CLINICS, (1998 Oct) 16 (4) 811-6, xiv. Ref: 27

TI Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes.

AU Douglas J.M.; Vontver L.A.; Stamm W.E.; et al.

SO Antimicrobial Agents and Chemotherapy, (1985) 27/2 (203-206).

TI Clinical studies with herpes simplex virus type 2 curtis strain vaccine.

AU Corey L.

SO Reviews of Infectious Diseases, (1991) 13/SUPPL. 11 (S904-S905).

TI Many avenues explored in search for herpes vaccines.

SO Drugs and Therapy Perspectives, (1995) 5/5 (7-8).

TI Emerging herpes vaccines.

AU Hanissian J.

CS J. Hanissian, Univ. of Pennsylvania Sch. of Med., Philadelphia, PA, United States

SO Infections in Medicine, (1997) 14/3 (205-206+208-209+247).

TI Herpes simplex virus type 2 epidemiology in the United States and the potential impact of a vaccine.

AU Garnett, G. P. [Reprint author]

SO International Journal of STD and AIDS, (2001) Vol. 12, No. Supplement 2, pp. 149-150. print.

TI Vaccines against genital herpes - Progress and limitations

AU Morrison L A (Reprint)

SO DRUGS, (6 MAY 2002) Vol. 62, No. 8, pp. 1119-1129.

TI Glycoprotein-D-adjuvant vaccine to prevent genital herpes

AU Stanberry et al,

SO New England Journal of Medicine (2002), 347(21), 1652-1661

TI Recent progress in herpes simplex virus immunobiology and vaccine research

AU Koelle D M (Reprint); Corey L

SO CLINICAL MICROBIOLOGY REVIEWS, (JAN 2003) Vol. 16, No. 1, pp. 96-+.

TI Development of prophylactic vaccines for genital and neonatal herpes

AU Jones, Cheryl A.; Cunningham, Anthony L.

SO Expert Review of Vaccines (2003), 2(4), 541-549

A review. **Over five decades numerous conventional candidate live attenuated and killed vaccines have failed to prevent genital**

herpes in clin. trials. However, a vaccine consisting of recombinant glycoprotein D from herpes simplex virus (HSV)-2 and deacylated monophosphoryl lipid A adjuvant has recently shown partial efficacy against clin. disease transmitted from HSV-1 and -2 seroneg. women (73-74%). Comparisons between the efficacy of this vaccine and previous failed candidates and their effects on the immune system should help guide development of better vaccines through selection of appropriate HSV proteins, adjuvants or cytokines and newer vaccine vectors, such as DNA vaccines, recombinant viral vaccines and specific HSV mutants.

TI Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease.

AU Kriesel J D; Spruance S L; Daynes R A; Araneo B A

SO JOURNAL OF INFECTIOUS DISEASES, (1996 Mar) 173 (3) 536-41. ROUTE OF ADMIN?????????

TI The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs.

AU McClements W L; Armstrong M E; Keys R D; Liu M A

SO VACCINE, (1997 Jun) 15 (8) 857-60. ROUTE OF ADMIN?????????